Zeneca and OncorMed to collaborate on cancer tests
This article was originally published in Clinica
Zeneca Diagnostics (UK) and OncorMed (US) are to collaborate on the development and commercialisation of new cancer tests. The companies will initially focus on using Zeneca's amplification refractory mutation system (ARMS) for PCR technology in OncorMed's colorectal k-ras and BRCA breast cancer gene tests. OncorMed currently uses labour-intensive mutation detection techniques such as single strand conformational polymorphism and DNA sequencing.